A Cochrane review [Abstract] 1 included 64 studies with a total of 9 771 subjects of any age, with and without evidence of cardiovascular disease. Pravastatin was compared to placebo for a period of 3 to 12 weeks.
Pravastatin 10 mg/day to 80 mg/day reduced LDL cholesterol by 22% to 32%, total cholesterol by 16% to 23%, and triglycerides by 6% to 20%. Pravastatin decresed blood LDL cholesterol by 3.4% (95% CI 2.2 to 4.6) for every 2-fold dose increase. Compared to other systematic reviews on statins, the slope of pravastatin dose response was less for LDL cholesterol than atorvastatin, rosuvastatin, fluvastatin, cerivastatin and pitavastatin. It was not possible to provide a good estimate of the incidence of harms associated with pravastatin due to lack of reporting of adverse effects in 48% of the studies.
For the recommended doses, pravastatin reduced LDL cholesterol (22% to 32%) similar to fluvastatin (21 to 33%), but less than atorvastatin (37% to 52%), rosuvastatin (41% to 55%), cerivastatin (23% to 41%), and pitavastatin (33% to 44%).
Date of latest search:
Primary/Secondary Keywords